Your browser doesn't support javascript.
loading
Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Kaira, Kyoichi; Tomizawa, Yoshio; Yoshino, Reiko; Yoshii, Akihiro; Matsuura, Masana; Iwasaki, Yasuki; Koga, Yasuhiko; Ono, Akihiro; Nishioka, Masaki; Kamide, Yosuke; Hisada, Takeshi; Ishizuka, Tamotsu; Shirai, Katsuyuki; Ebara, Takeshi; Saitoh, Jun-Ichi; Nakano, Takashi; Sunaga, Noriaki.
Afiliação
  • Kaira K; Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan. Electronic address: kkaira1970@yahoo.co.jp.
Lung Cancer ; 82(3): 449-54, 2013 Dec.
Article em En | MEDLINE | ID: mdl-24099666
PURPOSE: To determine the efficacy and safety of oral S-1 in combination with cisplatin and thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer (NSCLC). METHODS AND MATERIALS: S-1 (50mg/m(2)) was administered orally twice daily for 14 days, with cisplatin (40 mg/m(2)) on days 1 and 8 of each cycle every 3 weeks, for 2-4 cycles. Thoracic radiation therapy was administered in 2 Gy fractions five times weekly for a total dose of 60 Gy. The primary endpoint was the response rate, and secondary endpoints included progression-free survival, overall survival and safety. RESULTS: Forty-one patients were enrolled in this study. The objective response rate was 87.8% (98% CI: 77.8-97.8%). The median progression-free survival was 467 days (15.4 months), and the median survival time was 904 days (29.7 months). The overall survival rates at 1- and 2-years were 85.7% and 52.9%, respectively. Hematological toxicities included grade 3/4 neutropenia (17%) and grade 3/4 leukopenia (27%). No grade 3 febrile neutropenia was detected, and grade 3/4 non-hematological toxicities were also mild. A grade 3 gastrointestinal hemorrhage was observed in one patient. CONCLUSIONS: The combination of oral S-1 plus cisplatin with concurrent radiotherapy is a promising treatment with a high efficacy and lower toxicity in patients with locally advanced NSCLC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Oxônico / Tegafur / Cisplatino / Carcinoma Pulmonar de Células não Pequenas / Quimiorradioterapia / Neoplasias Pulmonares Tipo de estudo: Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2013 Tipo de documento: Article País de publicação: Irlanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Oxônico / Tegafur / Cisplatino / Carcinoma Pulmonar de Células não Pequenas / Quimiorradioterapia / Neoplasias Pulmonares Tipo de estudo: Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2013 Tipo de documento: Article País de publicação: Irlanda